Interactive case-based learning in ADPKD
Introduction
LEARNING OBJECTIVES
At the end of this program, participants will be able to:
- Evaluate risk progression in ADPKD
- Identify patients at high risk of progression
- Determine whether patients are suitable candidates for tolvaptan treatment
SECTION 3 CREDITS:
Speaking Volumes 3: Portraits of PKD has been approved by the Canadian Society of Nephrology and is an accredited Self-Assessment Program (Section 3), as defined by the Maintenance of Certification (MOC) Program of the Royal College of Physicians and Surgeons of Canada. Devised to achieve scientific integrity, objectivity and balance, this program was made possible through an unrestricted educational grant from Otsuka Canada Pharmaceutical Inc. (OCPI).
To claim two (2) credits per hour of educational activity, you must complete the Self-Assessment Test, save your results and the Certificate of Completion, and enter this activity into MAINPORT (http://www.mainport.org).
DISCLAIMER
This educational program was developed and reviewed by a panel of ten (10) Canadian nephrologists with experience in diagnosing and managing autosomal dominant polycystic kidney disease (ADPKD), and who have used ADPKD-specific medication in clinical trials and in real life.
There were no evidence-based clinical practice guidelines for the diagnosis and management of ADPKD at the time this program was developed. The opinions expressed in this program are those of the program faculty at the time the program was developed, and are not to be considered as directive.
CONTENT DEVELOPMENT COMMITTEE
Clinical Investigator, Division of Nephrology, St. Michael's Hospital
Assistant Professor, University of Toronto
Toronto, Ontario
Nephrologist, MUHC McGill, Glen Site
Associate Professor of Medicine, McGill University
Montreal, Quebec
Nephrologist, Sacré-Cœur de Montréal Hospital
Professor of Medicine and Molecular & Integrative Physiology, University of Montreal
Montreal, Quebec
Nephrologist, Division of Nephrology, University of Calgary
Clinical Assistant Professor, University of Calgary
Calgary, Alberta
Nephrologist, Toronto General Hospital, University Health Network
Professor of Medicine, University of Toronto
Toronto, Ontario
Director, Division of Nephrology, Laval University
Professor of Medicine, Laval University
Quebec City, Quebec
Nephrologist, Department of Medicine, Nova Scotia Health Authority
Medical Lead, Central Zone Renal Program, Nova Scotia Health Authority
Medical Lead, Pharmacy and Renal Program, Nova Scotia Health Authority
Professor of Medicine, Dalhousie University
Halifax, Nova Scotia
Nephrologist, The Scarborough Hospital
Medical Director, Scarborough Regional Nephrology Program
Scarborough, Ontario
Nephrologist and Hypertension Specialist, Sunnybrook Health Sciences Centre
HSF/NOSM Chair in Aboriginal and Rural Health Research
Professor of Medicine, University of Toronto Toronto, Ontario
Nephrologist, St. Michael's Hospital
Assistant Professor of Medicine, University of Toronto
Toronto, Ontario
Disclaimer
This program was made possible with the support of Otsuka Canada Pharmaceutical Inc. (“Sponsor”). The views expressed in this program do not necessarily reflect those of UKidney and the Sponsor. This program might include information about drugs or indications that have not been approved in Canada.
